Showing results (121-130 of 156) with videos related to
Sort By:
Pageof 16
Respiratory Medicine|January 22, 2008
Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once dailyEdward M Kerwin, Robert A Nathan, Eli O Meltzer, et al.International Journal of Molecular Sciences|August 10, 2024
Flow and On-Water Synthesis and Cancer Cell Cytotoxicity of Caffeic Acid Phenethyl Amide (CAPA) DerivativesAnthony Saucedo, Muppidi Subbarao, Mauricio Jemal, et al.International Journal of Chronic Obstructive Pulmonary Disease|March 11, 2017
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyEdward M Kerwin, Chris J Kalberg, Dmitry V Galkin, et al.Biopharmaceutics & Drug Disposition|June 23, 2009
Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to ratsXinyu Wang, Jihai Pang, Jacqueline A Maffucci, et al.International Journal of Chronic Obstructive Pulmonary Disease|August 29, 2015
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing dataAnthony D D'Urzo, Edward M Kerwin, Kenneth R Chapman, et al.International Journal of Chronic Obstructive Pulmonary Disease|March 19, 2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENTAnthony D D'Urzo, Dave Singh, James F Donohue, et al.Journal of AHIMA|October 6, 1991
Health record completion guidelines. American Health Information Management AssociationM P DeVitt, B M Haenke, J M Picukaric, et al.Advances in Therapy|August 4, 2021
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX TrialLeif H Bjermer, Isabelle H Boucot, Claus F Vogelmeier, et al.The American Journal of Medicine|December 1, 1980
Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathyD J Cutler, J M Isner, A W Bracey, et al.Respiratory Research|October 29, 2021
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trialClaus F Vogelmeier, Paul W Jones, Edward M Kerwin, et al.Pageof 16